Drugs / SGN-30
Trials 7 · a red edge is where a trial was stopped
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-06-01 | Pfizer | Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma pfizer.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGN-30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00079755 ↗ |
| Known as | Brentuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02623920 ↗ |
| Action | Inhibit | “Monoclonal antibodies, such as SGN-30, may interfere with the ability of cancer cells to grow and spread.” NCT00337194 ↗ |
| Modality | Monoclonal antibody | “Phase 1 testing of SGN-30, a chimeric monoclonal antibody for the treatment of CD30(+) malignancies, was conducted in a multicenter study.” PMID 18079362 ↗ Dec 2007 |
| Route | Intravenous | “received 6 weekly doses of intravenous SGN-30 at 4 dose levels (2, 4, 8, or 12 mg/kg).” PMID 18079362 ↗ Dec 2007 |